HOME > BUSINESS > Sun Pharma selects Samsung to manufacture psoriasis drug

Sun Pharma selects Samsung to manufacture psoriasis drug

Sun Pharma said it has inked a long-term agreement with Samsung BioLogics under which the Korean company will manufacture Tildrakizumab, a potential treatment for plaque psoriasis, for the Indian company.

Plaque psoriasis is an autoimmune condition which results in patches of thick, red, scaly skin.

The approximate value of the contract will be US$ 55.5 million, other financial details of the agreement are confidential, it said.

Commenting on its agreement with Samsung BioLogics, Mr Kirti Ganorkar, Global Head – Portfolio Management & Business Development, Sun Pharma said, “Samsung BioLogics is a globally renowned CMO. Through this partnership we will leverage Samsung’s manufacturing knowledge and world class quality systems to provide high quality products for the Tildrakizumab pipeline.”

TH Kim, President and CEO of Samsung BioLogics said: “Our collaboration with Sun Pharma is an important milestone for Samsung as it is a testament of our ability to provide reliable supply through its GMP-certified manufacturing facility to pharmaceutical companies, which aim to expand their global market.”

The filing for the investigational biologic has been accepted for review by the U.S. Food and Drug Administration (FDA) (May 2017) and the European Medicines Agency (EMA) (March 2017), the Indian company said.

Tildrakizumab is an investigational humanized, anti-IL-23p19 monoclonal antibody designed to selectively block the cytokine IL-23. With this precise targeting, tildrakizumab has the potential to help control the pathogenic cells responsible for the inflammatory process of psoriasis with limited impact on the rest of the immune system, Sun Pharma said.

“Phase-3 tildrakizumab data provide further evidence for the role of the IL-23 pathway in helping to control the inflammatory process of psoriasis,” it said.

The regulatory filings associated with tildrakizumab have been accepted for review by the FDA and EMA.

Follow ULTRA.news
Wipro opens Artificial Intelligence research facility in Israel University IT and outsourcing services provider Wipro said it will use students at Israel's largest university to jointly conduct research into artificial intelligence.The company inked an agreement with Tel Aviv University, Israel's largest institution of higher learning which is home ...
Glenmark Pharma gets UK OTC approval for anti-malarial medicine Glenmark Pharmaceuticals said it received approval from UK authorities for to sell its Maloff Protect anti-malarial medication without prescription.It contains atovaquone and proguanil hydrochloride, and has been available only as a prescription medicine in the UK.The Me...
Strides Shasun gets USFDA nod for nausea drug Pharmaceutical company Strides Shasun said it received approval from the United States Food & Drug Administration to sell nausea drug Promethazine Hydrochloride in the country.The US market for Promethazine Hydrochloride tablets is approximately USD 17 Million.It will be ...
Unichem Labs says USFDA completes inspection of Goa facility Unichem Laboratories said the US FDA has completed its inspection of the company's formulations manufacturing facility in Goa.Unichem Labs' formulations plant in GoaThe facility has received an Establishment Inspection Report, the company added."This receipt indica...
Zydus Cadila gets approval for obesity drug in USA Zydus Cadila said it received the final approval from the US FDA to market obesity drug Phentermine Hydrochloride.The drug will be marketed in the form of orally disintegrating tablets in strengths of 15 mg, 30 mg, and 37.5 mg.The drug is used to treat obesity in people w...
Zydus Cadila gets nod to sell ADHD drug in USA Nesher Pharmaceuticals, a subsidiary of Zydus Pharmaceuticals received final approval from the US Food and Drug Administration to sell generic drug Dextroamphetamine Sulfate.Dextroamphetamine is a central nervous system stimulant used in the treatment of Attention Deficit Hyp...
Zydus Cadila gets USFDA nod for Hepatitis B drug Zydus Cadila has received the final approval from the the US Food and Drug Administration to market Hepatitis B drug Entecavir.The drug has sales of $166.3 million in the US, and will be sold in 0.5 mg and 1 mg dosage.It will be produced at the group's formulations manufa...
Glenmark gets USFDA approval for generic joint-pain drug in US Glenmark Pharmaceuticals said it received final approval from the United States Food & Drug Administration for marketing a generic version of joint-pain drug Indocin of Iroko Pharmaceuticals.The drug has annual sales of approximately $6.3 million.With this, Glenmark’s ...
NIV to help Sun Pharma test Zika, Dengue and Chikungunya drugs Sun Pharma announced a tie-up with National Institute of Virology (NIV) under the Indian Council of Medical Research for testing various compounds for treating rapidly spreading viral infections -- Zika, Chikungunya and Dengue.The compounds will include those sourced from pl...
Lupin launches skin ointment in the US Pharma Major Lupin said it launched Desoximetasone cream for treating skin problems in the US market.The company had received approvals from the US Food and Drug Administration earlier.The drug is the generic equivalent of Tarot Pharma's Topicort, which had US sales of $...
Anil Ambani Group ties up with Thales for Rafale contracts Reliance Defence, the defence manufacturing arm of the Anil Ambani group, said it will form a joint venture in India with global defence manufacturer Thales to carry out some contracts related to the Rafale jet deal.The Indian company will hold 51% of the equity while the fo...
Alembic Pharma to launch generic version of AstraZeneca heart drug in USA Alembic Pharmaceuticals said it received approval from the US Food & Drug Administration for selling a generic equivalent of AstraZeneca's heart drug Atacand.Approval was granted for the sale of candesantan cilexetil in the dosage of 32 mg.Candesartan cilexetil is used ...
Glenmark Pharma buy rights to cancer drug from US firm Glenmark Pharmaceuticals said it entered into a licensing agreement with Boston-based biopharmaceutical company APC Therapeutics Inc for exclusive rights for a cancer drug.The agreement covers a small molecule based on Antigen Presenting Cell (APC) biology, the Indian compa...
Zydus Cadila gets USFDA approval for generic version of popular migraine drug Zydus Cadila said it received final approval from the US Food and Drug Administration to market migraine drug Eletriptan Hydrobromide in the US.The drug is currently marketed and manufactured by Pfizer Inc and sold in the US and Canada under the brand name Relpax.The two...
Lupin launches generic antidepressant in the US India's second biggest pharmaceutical company Lupin said it has launched the generic version of Valeant's Wellbutrin antidepressant tablet Wellbutrin XL in the US.Wellbutrin XL tablet has yearly US sales of USD 758 million or about Rs 5,000 cr.It is used for the treatment...
Aurobindo Pharma launches kidney drug in the US Aurobindo Pharma said it received final approval from the US Food & Drug Administration to manufacture generic version of kidney drug Renvela from Genzyme.Sevelamer Carbonate oral suspension, 0.8 gm and 2.4 gm is being launched immediately, the company said.The drug had ...
Lupin gets USFDA approval for pain relief drug Pharma Major Lupin said received final approval for launching a generic version of Mallinckrodt Inc.'s Roxicodone Tablets in the United States.The drug is used for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are...
Suven Life Sciences gets US, Australia patent for CNS molecule Suven Life Sciences Ltd said it got a patent from Australia and another from the US for a new molecule used for treating disorders associated with Neurodegenerative diseases.The 'new chemical entity' patent no 2014358652 from Australia is valid through 2032, while that from ...
India tablet sales fall 16%, but 4G picks up in Jan-Mar 2017 The tablet market in India continues to shrink as phones become larger and larger, numbers from CyberMedia Research showed, but more and more people are opting for connected tablets with 3G and 4G options built-in.The total number of tablet PCs sold in India fell 16% in the ...
Jet Airways inks codeshare agreement with Aeromexico Jet Airways said it inked an agreement with Aeromexico, the flag carrier airline of Mexico, to explore codeshare arrangements and shared frequent flyer programs. As part of the arrangement, both carriers will code on each other’s services between India and Mexico via common ...
Unichem Labs Ghaziabad plant inspected by USFDA Generic drug manufacturer Unichem Laboratories said its formulations manufacturing facility at Ghaziabad has successfully exited an inspection by the US Food and Drug Administration.Inside a Unichem plantIt received an Establishment Inspection Report (EIR) from the USFDA...
Zydus Cadila gets USFDA approval for generic form of colitis drug Lialda Zydus Cadila said the US Food and Drug Administration has given the final approval to market the company's Mesalamine Delayed-Release Tablets in the US market.Zydus Cadila was the first to file an Abbreviated New Drug Application (ANDA) for a generic version of Lialda.L...
Strides Shasun gets USFDA approval for ibuprofen Pharmaceuticals manufacturer Strides Shasun said it received approval from the United States Food & Drug Administration (USFDA) for ibuprofen Tablets 200 mg for over the counter sales.According to Ri data, the US market for ibuprofen Tablets USP 200 mg (OTC) is approximately...
Samsung Galaxy J2 beats Redmi Note 3 & 4 as most popular smartphone in India Samsung J2 is the most widely used smartphone in IndiaThe humble Samsung Galaxy J2, launched two years ago, is the most widely used smartphone in India, beating hot-selling models like Xiaomi Redmi Note 3 & 4 CyberMedia Research said.Samsung J2 is the most widely used smartp...
Xiaomi at No.2, overtakes Vivo, Oppo in Indian smartphone market Xiaomi has emerged as the second biggest smartphone brand in India after Samsung as its smash hit Redmi Note 4 broke sales records, according to market share numbers for the first three months of the year.The numbers also revealed that for the first time in eight years, t...